This article has been disseminated on behalf of Quantum BioPharma Ltd. and may include paid advertising.
Quantum BioPharma (NASDAQ: QNTM) (CSE: QNTM), a biopharmaceutical company focused on advancing innovative therapies and technologies, was featured on the latest episode of The BioMedWire Podcast, where co-founder and executive co-chair Anthony Durkacz discussed the company’s lead drug candidate, Lucid-MS. Durkacz said the therapy is being developed to address mobility loss associated with multiple sclerosis by targeting nerve damage, an area he believes remains unmet by currently available treatments.
Durkacz also discussed Quantum BioPharma’s commercial alcohol metabolism product, unbuzzd(TM), which is designed to accelerate blood alcohol metabolism and is currently available in the U.S. market. Looking ahead, he highlighted the company’s upcoming Phase 2 clinical trial for Lucid-MS, which will be the first study to evaluate the drug candidate in multiple sclerosis patients following Phase 1 testing in healthy volunteers.
NOTE TO INVESTORS: The latest news and updates relating to QNTM are available in the company’s newsroom at https://nnw.fm/QNTM
Please see full terms of use and disclaimers on the NetworkNewsWire website applicable to all content provided by NNW, wherever published or republished: http://NNW.fm/Disclaimer